Search

everythinglearnresearchcommunity

for

Search:↓

Chemotherapy for prostate, bladder, and testicular cancer patients commonly causes hair loss, fatigue, and decreased appetite.

Hormone therapy for breast cancer often leads to sexual issues like vaginal dryness and decreased libido.

Understanding breast cancer requires considering both medical advancements and social influences.

Docetaxel and paclitaxel for breast cancer can cause permanent, severe hair loss.

Multimodal primary treatment improves survival in premenopausal breast cancer patients and is also beneficial for postmenopausal women.

Electric pulse treatments for breast cancer show promise in being safer and more effective, with fewer side effects.

Scalp cooling is largely ineffective in preventing hair loss from breast cancer chemotherapy.

Taking 5α-reductase inhibitors does not significantly increase the risk of breast cancer in men.

Spironolactone use is not linked to an increased risk of breast cancer, but caution is advised for high-risk patients.

Hair loss from hormone therapy in breast cancer patients can be improved with minoxidil treatment.

The combination of gemcitabine and vinorelbine is effective and safe for treating elderly patients with advanced breast cancer previously treated with anthracyclines and taxanes.

Taking 5-alpha reductase inhibitors does not increase breast cancer risk in men.

Topical minoxidil improves hair loss in 80% of women with breast cancer undergoing endocrine therapy.

Formestane is a preferred second-line treatment for advanced breast cancer in postmenopausal women because it's effective and has fewer side effects.

Coumarin derivatives show promise as anti-estrogenic agents for treating breast cancer, with some in clinical trials.

Dihydrotestosterone causes p27 protein breakdown in ovarian and breast cancer cells by binding with SKP2.

Chemotherapy can cause significant hair thinning and changes in hair texture, while tamoxifen has a smaller effect.

Hair and scalp pain is more common and severe in breast cancer patients on chemotherapy than those on tamoxifen.

CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.

Nutraceuticals that promote hair growth do not reduce tamoxifen's effectiveness in breast cancer treatment.

Nutritional education reduces chemotherapy side effects and improves health in breast cancer patients.

The trial will test if YH0618 granule prevents hair loss in breast cancer patients during chemotherapy.

CK 5/6 expression in breast cancer is linked to negative hormone receptor status and higher tumor grade.

Oncologists should better understand the unique impact of hair loss on Black breast cancer patients to offer more compassionate care.

Breast cancer hormone therapy can cause hair loss, which can be treated with daily applications of specific topical solutions like minoxidil and hydrocortisone butyrate.

WNT10B is linked to cancer development and affects survival and disease progression in various cancers.

Hair loss is a common, often overlooked side effect of hormone treatments for breast and prostate cancer.

Oral paclitaxel plus encequidar improved tumor response and caused less neuropathy but more serious infections than intravenous paclitaxel.

Medicines for enlarged prostate may raise the risk of breast growth and tenderness but not breast cancer.

Certain HSD3B1 gene types are linked to worse prostate cancer outcomes and affect treatment response and other health conditions.